Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives Average Rating of “Hold” from Brokerages

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has received a consensus rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $4.9167.

A number of research analysts have recently commented on VVOS shares. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Finally, Ascendiant Capital Markets reduced their target price on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, December 3rd.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $1.22 on Friday. Vivos Therapeutics has a 1 year low of $1.19 and a 1 year high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The stock has a market capitalization of $12.77 million, a PE ratio of -0.69 and a beta of 6.94. The company’s 50 day simple moving average is $1.59 and its two-hundred day simple moving average is $2.31.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Connective Capital Management LLC purchased a new position in shares of Vivos Therapeutics during the third quarter worth about $620,000. DRW Securities LLC raised its stake in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in Vivos Therapeutics in the second quarter valued at approximately $220,000. XTX Topco Ltd bought a new stake in Vivos Therapeutics during the second quarter valued at approximately $65,000. Finally, Acorn Wealth Advisors LLC bought a new stake in Vivos Therapeutics during the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.